top of page
Glass Buildings

Investor Letter

Amplify Your Investment Portfolio: Invest Confidently in KIC Ventures to Revolutionize Spine Surgery with Next-Generation AxioMed Viscoelastic Disc Replacements and NANISX Outpatient LESS™ Technologies

Dear Valued Investor Partner

I trust this letter finds you in good health and high spirits. On behalf of the entire KIC Ventures team, I'm thrilled to extend an exclusive opportunity for you to join our Series A round, enabling you to become a valued stakeholder in KIC Ventures and its distinguished portfolio companies


Imagine a world where spine surgery is minimally invasive, outpatient-focused, and delivers faster recovery that is accessible for patients. This is the future KIC Ventures is building, and we invite you to partner with us on this transformative journey.

Industry Outlook:

Analysts project substantial growth in sales of spinal surgery implants, instruments, pharmaceuticals, and novel treatments for chronic back pain, indicating a significant market opportunity to address the $250 billion annual economic cost of chronic back pain, aligning returns with societal impact. The spine industry represents a promising sector that has strong macro fundamentals and low correlation to traditional markets providing diversification to an investment portfolio.


Advancing Total Disc Replacement Spine Surgery.

At the core of our portfolio lies the revolutionary AxioMed viscoelastic total disc replacement platform, encompassing cervical, lateral lumbar, and anterior lumbar discs, complemented by the groundbreaking AxioMedX smart disc featuring patented sensor technologies. The demand for our AxioMed disc replacement is steadily on the rise, with patients globally expressing their appreciation and voicing their needs for AxioMed's solution to restore natural spine motion on platforms such as YouTube and Facebook (Watch Video). Your support is pivotal in helping us prepare for the lumbar disc FDA approval and USA launch in 2025 and the re-commercialization of the cervical disc overseas.



Pioneering Outpatient Less Exposure Spine Surgery (LESS™) Technologies.

At NANISX, our passion is deeply anchored in transforming the landscape of outpatient spine surgery for orthopedic surgeons, neurosurgeons, and interventional pain management. NANISX is dedicated to minimizing surgical intervention while maximizing patient outcomes. Our team of engineers and physicians, united in purpose, is continuously innovating to redefine interventional spine surgery. Our procedures, characterized by safety, simplicity, and minimal incisions, underscore our dedication to swift and effective patient recovery.  There are now 9,000+ surgery centers in the USA, and NANISX is democratizing outpatient spine surgery allowing more patients to be treated safely and effectively while avoiding major traditional spine surgery in hospitals.


Key Achievements:

  • Trained 300+ interventional pain management physicians on our devices.

  • Published research supporting the effectiveness of our devices.

Key Portfolio:

  • NANISX's portfolio includes profitable revenue-generating technologies:

    • NanoFuse Biologics: An FDA-approved synthetic bioactive glass plus DBM combination to regenerate bone growth.

    • InSpan: An interspinous fixation device for minimally invasive lumbar spinal fixation.

    • Sacrix: A multithreaded sacroiliac joint fusion titanium implant.

    • FacetFuse: A unique transfacet pedicle screw titanium implant for facet fusion.


Financial Landscape


KIC Ventures is strategically positioned to seize opportunities in this era of innovation. Non-fusion technologies like AxioMed disc replacements are surging at a 11.4% CAGR, nearly triple the overall market growth, predicted to reach a market size of $2.4 billion by 2034, according to Fact.MR, offering a lucrative window for early investors. The potential IPO present an exciting avenue for investors to participate in the growth of this next-generation spine company.


Since navigating the challenges posed by the pandemic, starting in 2022, NANISX has consistently surpassed growth targets, achieving an impressive 40% year-over-year growth while upholding profitability and EBITDA growth. In 2024, with your support, we are poised for an extraordinary 40-50% growth in NANISX revenues over 2023, setting the stage for potential acquisitions, strategic partnerships or initial public offerings (IPOs). These strategic moves are anticipated to propel KIC Ventures into accelerated global revenue growth, reaching a valuation in the billions.


KIC Ventures:

KIC Ventures has raised over $20 Million into its portfolio companies and has now opened this Series A round offering ownership directly in the parent investment holdings, KIC Ventures, as a unique opportunity to accelerate existing portfolio revenue growth profitably and achieve value inflection milestones toward potential acquisitions, strategic partnerships or target IPOs. By joining us, you gain immediate exposure to both the established success of AxioMed and NANISX, alongside several other promising ventures under the KIC Ventures umbrella.


This limited Series A funding round presents a unique opportunity to invest at a strategically reduced valuation as a diversified holding for our investors to see an attractive multiple return on investment.

Meet Two Of Our Key Team Leaders:

  • Dr. Kingsley R Chin, Founding Surgeon and CEO: A board-certified orthopedic spine surgeon and Harvard Medical School (Honors) graduate, Dr. Chin is a 20+ year pioneer in outpatient spine surgery LESS™ technologies and techniques.

  • Dr. Erik Spayde, Chief Medical Officer: A board-certified orthopedic spine surgeon and Harvard Medical School graduate, Dr. Spayde drives our clinical translational innovations of our LESS™ technologies from bedside to market and ensures that KIC Ventures remains at the forefront of transformative advancements.



As KIC Ventures anticipates a market upturn and potential IPOs for AxioMed and NANISX, investors are presented with a unique opportunity.  Our strategic vision positions investors to ride the wave of innovation and transformative change, contributing to healthcare evolution. With visionary founders and dynamic leaders, KIC Ventures is ready to lead the way in shaping the future of outpatient spine surgery.


It's exhilarating to be at the cutting edge of spine surgery innovation. Thank you for considering an investment in KIC Ventures. We express our profound gratitude for your support and look forward to warmly welcoming you as a crucial part of our journey.


We invite you to explore our website at

Warm regards,

Aditya Humad

Cofounder & Chief Financial Officer

KIC Ventures


How to

Investment Opportunities


This presentation is subject to and conditioned upon the Investor’s (a) reviewing a Confidential Private Placement Memorandum; (b) executing a Subscription Agreement and Investor Questionnaire; (c) being qualified by the Issuer as an Accredited Investor under Regulation D. Investor shall pay no investment funds until all of the foregoing have occurred to the satisfaction of Company as the Issuer. This presentation does not take into account, nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. Company reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to notify the recipient thereof.

bottom of page